P168 The effect of fluticasone propionate/formoterol fumarate combination therapy on quality of life scores in asthma patients

The aim of the study was to assess efficacy and safety of 24-month treatment with Seretide (salmeterol / fluticasone propionate, 100 / 1 000 mcg daily) or Flixotide (fluticasone propionate, 1 000 mcg daily) in 105 steroid-dependent asthma patients aged 18 to 60 yrs who had received oral steroids for at least 6 months but not longer than 10 years. Methods. The study was comparative, randomized, multicentre, open in parallel groups (15 visits with 2-week intervals). Reduction of oral steroid doses started at the 3-rd visit. Results. In spite of the continual treatment with oral steroids patients did not reach asthma control. After 6-month therapy with fluticasone propionate or salmeterol / fluticasone propionate the maintaining dose of prednisolone was 6 times lower in comparison with baseline. Moreover, oral steroids were abolished in each second patient receiving Seretide and each third patient receiving Flixotide. The asthma control and quality of life significantly increased. Conclusion. The therapy with fluticasone propionate or salmeterol / fluticasone propionate allows to reduce doses of oral steroids and to cease oral steroids in most causes. Moreover, the patients can maintain good asthma control.

Download Full-text

Research of quality of life of COPD and asthma patients

Pneumologie ◽

10.1055/s-2005-864267 ◽

2005 ◽

Vol 59 (S 1) ◽

Author(s):

T Zhukava

Keyword(s):

Quality Of Life ◽

Asthma Patients

Download Full-text

MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review

International Archives of Allergy and Immunology ◽

10.1159/000516417 ◽

2021 ◽

pp. 1-10

Author(s):

Ludger Klimek ◽

William E. Berger ◽

Jean Bousquet ◽

Paul K. Keith ◽

Peter Smith ◽

...

Keyword(s):

Quality Of Life ◽

Allergic Rhinitis ◽

Fluticasone Propionate ◽

Treatment Options ◽

Symptomatic Disease ◽

Intranasal Corticosteroids ◽

Need For Treatment ◽

Ocular Symptoms ◽

Symptom Complex

Allergic rhinitis (AR) is prevalent, and many patients present with moderate-to-severe symptomatic disease. The majority of patients are not satisfied with their AR treatment, despite the use of concurrent medications. These gaps underscore the need for treatment with more effective options for moderate-to-severe AR. The authors’ objective was to review systematically the efficacy and safety of MP-AzeFlu for the treatment of AR. The primary outcomes studied were nasal, ocular, and total symptoms. Other outcomes included time to onset and of AR control, quality of life, and safety. Searches of PubMed and Cochrane databases were conducted on May 14, 2020, with no date restrictions, to identify publications reporting data on MP-AzeFlu. Clinical studies of any phase were included. Studies were excluded if they were not in English, were review articles, did not discuss the safety and efficacy of MP-AzeFlu for AR symptoms. Treatment of AR with MP-AzeFlu results in effective, sustained relief of nasal and ocular symptoms, and faster onset and time to control compared with intranasal azelastine or fluticasone propionate. Long-term use of MP-AzeFlu was safe, with benefits in children, adults, and adults aged ≥65 years. Other treatment options, including fluticasone propionate and azelastine alone or the combination of intranasal corticosteroids and oral antihistamine, do not provide the same level of efficacy as MP-AzeFlu in terms of rapid and sustained relief of the entire AR symptom complex. Furthermore, MP-AzeFlu significantly improves patient quality of life. MP-AzeFlu is a currently available combination that may satisfy all these patient needs and expectations.

Download Full-text

Long-Term Effects of Doxazosin, Finasteride and Combination Therapy on Quality of Life in Men with Benign Prostatic Hyperplasia

The Journal of Urology ◽

10.1016/j.juro.2013.01.061 ◽

2013 ◽

Vol 190 (1) ◽

pp. 187-193 ◽

Cited By ~ 16

Author(s):

Chyng-Wen Fwu ◽

Paul W. Eggers ◽

Steven A. Kaplan ◽

Ziya Kirkali ◽

Jeannette Y. Lee ◽

...

Keyword(s):

Quality Of Life ◽

Benign Prostatic Hyperplasia ◽

Combination Therapy ◽

Prostatic Hyperplasia ◽

Long Term Effects

Download Full-text

ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.tps5608 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. TPS5608-TPS5608

Author(s):

Toon Van Gorp ◽

Mansoor Raza Mirza ◽

Alain Lortholary ◽

David Cibula ◽

Axel Walther ◽

...

Keyword(s):

Quality Of Life ◽

Endometrial Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Combination Therapy ◽

Stage I ◽

Newly Diagnosed ◽

Phase 3 ◽

Eortc Qlq

TPS5608 Background: Pembrolizumab, a selective humanized anti–PD-1 monoclonal antibody, has demonstrated activity in patients with previously treated mismatch repair (MMR) deficient (dMMR; 57.1% ORR as monotherapy and 63.6% ORR as combination therapy with lenvatinib) and MMR proficient (pMMR; 36.2% ORR as combination therapy with lenvatinib) endometrial cancer (EC). ENGOT-en11/GOG-3053/KEYNOTE-B21 is a phase 3, randomized, double-blind study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with EC. Methods: Eligible patients are ≥18 years old with newly diagnosed, histologically confirmed high-risk (stage I/II non-endometrioid, stage III/IVa, p53 abnormality) EC (carcinoma or carcinosarcoma) following surgery with curative intent with no evidence of disease post-operatively or on imaging, and without prior systemic therapy/radiotherapy. In total, ̃990 patients are randomized to receive pembrolizumab 200 mg or placebo Q3W for 6 cycles + chemotherapy (carboplatin area under the curve [AUC] 5 or 6 + paclitaxel 175 mg/m2 Q3W or carboplatin AUC 2 or 2.7 + paclitaxel 60 mg/m2 QW) in stage 1. Patients receive pembrolizumab 400 mg or placebo Q6W for 6 cycles in stage 2 per their treatment assignment. At the investigator’s discretion, radiotherapy (external beam radiotherapy [EBRT] and/or brachytherapy) ± radiosensitizing cisplatin 50 mg/m2 (days 1 and 29) may be administered after completion of chemotherapy. Randomization is stratified by MMR status (pMMR vs dMMR) and, within pMMR, by planned radiation therapy (cisplatin-EBRT vs EBRT vs no EBRT), histology (endometrioid vs non-endometrioid), and International Federation of Gynecology and Obstetrics (FIGO) surgical stage (I/II vs III/IVA). Dual primary endpoints are disease-free survival (DFS; per investigator assessment) and overall survival (OS), both estimated by the Kaplan-Meier method, with a stratified log-rank test to assess treatment differences and a Cox proportional hazard model with Efron’s method of tie handling to assess the magnitude of treatment differences. Secondary endpoints include DFS (per blinded independent central review), DFS (per investigator assessment) and OS by biomarker status (PD-L1 and tumor mutational burden), safety (per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0) and quality of life (per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 [EORTC QLQ-C30] and Endometrial Cancer Module [EORTC QLQ-EN24]). The study began enrollment in December 2020. Clinical trial information: NCT04634877.

Download Full-text

Impact of stimulating cognitive-motor training on neuropsychological status and quality of life in patients with Parkinson's disease

Neurology neuropsychiatry Psychosomatics ◽

10.14412/2074-2711-2018-4-65-71 ◽

2018 ◽

Vol 10 (4) ◽

pp. 65-71

Author(s):

Yu. N. Bykov ◽

T. B. Bender ◽

Yu. N. Vasiliev ◽

A. N. Kalyagin ◽

Т. М. Maksikova ◽

...

Keyword(s):

Quality Of Life ◽

Parkinson’S Disease ◽

Parkinson's Disease ◽

Combination Therapy ◽

Mobile Devices ◽

Physical Functioning ◽

Motor Training ◽

Neuropsychological Status ◽

Sf 36

Motor and non-motor symptoms are identified in the clinical picture of Parkinson's disease (PD). Among its non-motor manifestations, cognitive impairment (CI) and emotional disorders play a special role in PD. It is important to search for new forms and methods of cognitive therapy in patients with PD.Objective:to analyze neuropsychological status and quality of life (QOL) in PD patients and to evaluate the efficiency of personalized combination therapy with a stimulating cognitive motor training on computer and mobile devices in these patients.Patients and methods. The investigation enrolled 112 patients with PD. A study group included 56 PD patients who received a cycle of combination therapy with cognitive-motor training on PC and mobile devices; a control group consisted of 56 PD patients who had only a drug therapy cycle. To evaluate neuropsychological status and QOL, the investigators used the Montreal Cognitive Assessment (MoCA), the McNair and Kahn memory self-evaluation scale, the Hospital Anxiety and Depression Scale (HADS), and the 36-Item Short Form Health Survey (SF-36) questionnaire.Results and discussion. According to MoCA scores, CI of varying severity was diagnosed in the majority of patients: in 75 and 80.4% in the study and control groups, respectively. Depressive syndrome was detected in 53.6 and 64.3% in these groups, respectively. According to the SF-36, the physical status of patients had the greatest effect in reducing their QOL. There were treatment-induced statistically significant positive changes for the following domains: physical functioning (p<0.01), role-physical functioning (p<0.001), pain intensity (p<0.01), general health (p<0.01), role emotional (p<0.0001), and mental health (p<0.01).Conclusion.The investigation has shown the efficiency of personalized therapy including stimulating cognitive-motor training on computer and mobile devices, which improves neuropsychological status and QOL in patients with PD.

Download Full-text